Skip to content

Laskimonsisäisesti annetun rasvaemulsion kyky sitoa bupivakaiinia verenkierrossa

Laskimonsisäisesti annetun rasvaemulsion kyky sitoa bupivakaiinia verenkierrossa

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2010-021446-21-FI
Enrollment
8
Registered
2010-08-12
Start date
2010-12-28
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The study is performed on healthy volunteers, investigating lipid resuscitation from local anesthetic intoxication. MedDRA version: 12.1 Level: LLT Classification code 10066766 Term: Acute drug intoxication

Interventions

Trade Name: Intralipid 200 mg/ml Pharmaceutical Form: Intravenous infusion INN or Proposed INN: Sojae ol. purif. CAS Number: 8001227 Other descriptive name: SOYA OIL Concentration unit: mg/ml milligra

Sponsors

Per Rosenberg
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: -Male -Age 33-55 -Anesthetists or nurse anesthetists Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: -Chronic diseases, especially cardiac or lung.

Design outcomes

Primary

MeasureTime frame
Main Objective: Measuring the evolution of plasma bupivacaine concentration over time concurrently with a lipid emulsion infusion.;Secondary Objective: Measuring the possible sedation and cardiac effects of intravenous bupivacaine.;Primary end point(s): Plasma bupivacaine concentrations at the start of the experiment, after 1 mg/kg slow infusion of bupivacaine, 5, 10, 20 and 30 minutes after the end of the bupivacainen infusion during the lipid emulsion infusion.

Countries

Finland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026